Drug Repositioning banner
- Jul. 25, 2012 - MINNEAPOLIS --
Since the development of new drugs can be time consuming and expensive, drug repositioning has emerged as a potentially cost-effective and quicker alternative to provide new drugs for pharmaceutical companies’ waning pipelines. Approved drugs have already met with the FDA’s approval therefore, the early stages of drug development can be bypassed. By mining existing drugs for new uses, researchers can focus instead on the clinical testing portion of the process. This shortens the development timeline and gets new treatments to patients faster. With new technologies and approaches, drug repositioning has become more streamlined and less accidental than it was in the past. By using a more systematic approach, existing compounds are being tested for both common and neglected diseases faster and with more success.
The 2nd Annual Drug Repositioning Conference to be held on October 23-24, 2012 in San Francisco, CA will feature a variety of speakers from academia, industry, non-profits and government.
Their perspectives will provide insight into the field of drug repositioning and the challenges and successes in getting a repositioned drug to the marketplace.
Building on last year’s conference, the 2nd Annual Drug Repositioning Conference will discuss what has changed in the last year and what continues to drive interest in drug repositioning.
Case studies will give attendees concrete examples of successfully repositioned drugs and there will be a focus on the best pathway to success for repositioning drugs.
David Cipolla, Senior Director of Pharma Sciences at Aradigm Corporation, will present on “Repositioning Drugs using Formulation and Delivery Technology.”
This session will focus primarily on repurposing using the inhalation route and will include repositioning of drugs for administration by inhalation to treat lung disease including early asthma medications, fungal and bacterial infections in the lung, lung cancer, and prevention of organ (lung) rejection. He will also discuss repositioning of a drug for administration by inhalation for systemic effect, including proteins and peptides such as insulin, GH, EPO, PTH, and IFNs.
Steve Jenner, VP Marketing at Zogenix, Inc., will present on “Repositioning an Underutilized Gold-standard Treatment by Leveraging Novel Delivery Technology: A Case Study of Sumavel®DosPro®
for Treatment of Migraine.” He will share on connecting the market need with the right drug delivery solution, differentiating that solution from the competition, and positioning the new solution for wide acceptance. He will also discuss development of the drug/device combination product using the 505b2 regulatory pathway.
Please visit http://www.drugrepositioningconference.com
for a preliminary agenda and information on how to register to attend.Photo: